Your session is about to expire
← Back to Search
Other
Yamani-15/5 chemical solution for Peripheral Arterial Disease
Phase 1
Waitlist Available
Led By Houssam Farres, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up compared to baseline
Awards & highlights
Study Summary
This trial will test whether a new solution can help with vascular calcification in patients with severe peripheral arterial disease who are scheduled for limb amputation.
Eligible Conditions
- Peripheral Arterial Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility
Secondary outcome measures
Safety as measured by the number of participants with treatment-related adverse events as assessed by Common Toxicity Criteria for Adverse Effects v4.0.
Trial Design
1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Infusion of Yamani-15/5 chemical solution.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,213 Previous Clinical Trials
3,767,011 Total Patients Enrolled
4 Trials studying Peripheral Arterial Disease
280 Patients Enrolled for Peripheral Arterial Disease
Houssam Farres, MDPrincipal InvestigatorMayo Clinic
3 Previous Clinical Trials
92 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger